Lecithin as a therapeutic agent in ulcerative colitis

Digestive Diseases

Volumn 31, Issue 3-4, 2013, Pages 388-390

  Stremmel, Wolfgang ^a   Gauss, Annika ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Lecithin; Mucus; Phosphatidylcholine; Ulcerative colitis

Indexed keywords

BILE ACID; CHOLINE; FATTY ACID; MUCIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE; RIFAXIMIN;

BACTERIAL TRANSLOCATION; COLITIS; COLON FLORA; COLON MUCOSA; COMPARATIVE STUDY; CONFERENCE PAPER; CROHN DISEASE; ENTERITIS; ENZYME ACTIVITY; FECES MICROFLORA; GASTROINTESTINAL ENDOSCOPY; HUMAN; HYDROPHOBICITY; ILEUM; ILEUM MUCOSA; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; MUCUS; PATHOGENESIS; PERMEABILITY BARRIER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM MUCOSA; SECRETION RATE; ULCER HEALING; ULCERATIVE COLITIS; BIOLOGICAL MODEL; COLITIS, ULCERATIVE; PATHOPHYSIOLOGY; ANTIINFLAMMATORY ACTIVITY; DELAYED RELEASE FORMULATION; NONHUMAN;

COLITIS, ULCERATIVE; HUMANS; LECITHINS; MODELS, BIOLOGICAL;

EID: 84888270161     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000354707     Document Type: Conference Paper

References (21)

1. Shirazi T, Longman RJ, Corfield AP, Probert CSJ: Mucins and inflammatory bowel disease. Postgrad Med J 2000; 76: 473-478.
2. Lamont JT: Mucus: the front line of intestinal mucosal defense. Ann NY Acad Sci 1992; 664: 190-201.
3. DeSchryver-Kecskemeti K, Eliakim R, Carroll S, Stenson WF, Moxley MA, Alpers DH: Intestinal surfactant-like material. A novel secretory product of the rat enterocyte. J Clin Invest 1989; 84: 1355-1361.
4. Butler BD, Lichtenberger LM, Hills BA: Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol 1983; 244:G645-G651.
5. Hicks AM, DeLong CJ, Thomas MJ, Samuel M, Cui Z: Unique molecular signatures of glycerophospholipid species in different rat tissues analyzed by tandem mass spectrometry. Biochim Biophys Acta 2006; 1761: 1022-1029.
6. Lichtenberger LM: The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995; 57: 565-583.
7. Willumeit R, Schuster A, Iliev P, Linser S, Feyerabend F: Phospholipids as implant coatings. J Mater Sci Mater Med 2007; 18: 367-380.
8. Guo W, Andersson R, Odselius R, Ljungh A, Wadström T, Bengmark S: Phospholipid impregnation of abdominal rubber drains: resistance to bacterial adherence but no effect on drain-induced bacterial translocation. Res Exp Med (Berl) 1993; 193: 285-296.
9. Hills BA: Surface-active phospholipid: a Pandora's box of clinical applications. 2. Barrier and lubricating properties. Intern Med J 2002; 32: 242-251.
10. Ehehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, Stremmel W: Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol 2004; 39: 737-742.
11. Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R: Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009; 15: 1705-1720.
12. Braun A, Schoenfeld U, Welsch T, Kadmon M, Funke B, Gotthardt D, Zahn A, Autschbach F, Kienle P, Zharnikov M, Grunze M, Stremmel W, Ehehalt R: Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. Int J Colorectal Dis 2011; 26: 898-998.
13. Hills BA: Gastric mucosal barrier: evidence for Helicobacter pylori ingesting gastric surfactant and deriving protection from it. Gut 1993; 34: 588-593.
14. Ehehalt R, Jochims C, Lehmann WD, Erben G, Staffer S, Reininger C, Stremmel W: Evidence of luminal phosphatidylcholine secretion in rat ileum. Biochim Biophys Acta 2004; 1682: 63-71.
15. Alpers DH, Zhang Y, Ahnen DJ: Synthesis and parallel secretion of rat intestinal alkaline phosphatase and a surfactant-like particle protein. Am J Physiol 1995; 268:E1205-E1214.
16. Engle MJ, Grove ML, Becich MJ, Mahmood A, Alpers DH: Appearance of surfactant-like particles in apical medium of Caco-2 cells may occur via tight junctions. Am J Physiol 1995; 268:C1401-C1413.
17. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P: Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481.
18. Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R: Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005; 54: 966-971.
19. Stremmel W, Ehehalt R, Autschbach F, Karner M: Efficacy of retarded release phosphatidylcholine for treatment of chronic, steroid refractory ulcerative colitis. Ann Intern Med 2007; 147: 603-610.
20. Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M: Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose-finding study. J Clin Gastroenterol 2010; 44:e101-e107.
21. Karner M, Kocjan A, Stein J, v. Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Hanemann A, Zuelch F, Keilhauer G, Stremmel W: Modified release phosphatidylcholine 'LT-02' in active ulcerative colitis: a randomized, placebo-controlled multicentre study (abstract). Gastroenterology 2012; 142:suppl 1.